BIOXCEL THERAPEUTICS INC (BTAI)

The Next Wave of Health AI: Analysts Highlight Breakthroughs in Clinical Trials and Patient Care

USA News Group  Commentary Issued on behalf of Avant Technologies Inc.   Vancouver, BC – December 17, 2024  – USA News Group News Commentary – Artificial intelligence (AI) is on the brink of becoming a critical resource in healthcare, moving beyond its status as a novel concept. With over 800 FDA-cleared AI applications already in […]

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing...

BioXcel Therapeutics Announces Proposed Public Offering

NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing...

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia...

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...

BioXcel Therapeutics to Present at ThinkEquity Conference

NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 ~40 million Americans go to emergency department annually after a traumatic...

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for...

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Estimated 23 million annual agitation episodes in the at-home setting 1-3  No FDA-approved therapies in the at-home setting for acute treatment of...

BTAI Stock Earnings: BioXcel Therapeutics Beats EPS, Beats Revenue for Q2 2024

BTAI stock results show that BioXcel Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

BTAI Stock Earnings: BioXcel Therapeutics Beats EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioXcel Therapeutics (NASDAQ:BTAI) just reported results for the second quarter...

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

Planning initiation of SERENITY At-Home pivotal Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or...

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each...

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...

BTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024

BTAI stock results show that BioXcel Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

     Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation ...

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer...

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies...

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN,...

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing...

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501...

Commit To Purchase BioXcel Therapeutics At $1.50, Earn 19.6% Annualized Using Options

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug...

7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode

Bullish speculators could have their opportunity to blow up the bears with these short-squeeze stocks to buy.

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial...

UBS cuts BioXcel to neutral; cites regulatory issues, financing (NASDAQ:BTAI)

UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end